United States · 
What does Latterell Venture Partners invest in?
Latterell Venture Partners invests most often at Series B and Series C (64% of the rounds on record), in sectors such as Wellbeing, Mental Health and Longevity.
Latterell Venture Partners highlights
- 01
29 rounds on record
- 02
Mostly Series B and Series C: 64% of its rounds
- 03
Sole investor in 2 rounds, median $12M
- 04
6 exits from the portfolio
What they do
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- WellbeingMental HealthLongevity
- Based in
- San Francisco, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first29 appearances
- 2012
7 rounds
- Dec
- Oct
- Apr
- Mar
- Jan
- Jan
- Jan
- 2011
2 rounds
- Nov
- May
- 2010
5 rounds
- Oct
- Oct
- Aug
- Jun
- Mar
- 2009
5 rounds
- Jul
- Jun
- Apr
- Mar
- Mar
- 2008
2 rounds
- Nov
- Jun
- 2007
5 rounds
- Aug
- Jul
- May
- May
- Jan
- 2006
1 round
- Jan
- 2005
1 round
- Mar
- 2004
1 round
- Jun
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 6 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What they claim to have backed
From their own portfolio page (on their website)
2 of 10 we have independently watched raise
InovaLabsViractaEvokeForteBioMeritageOncoMedPathwayProteinSimpleTetraLogicTranscend
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed6 in all
Meritage PharmaBought by Shire$245MFeb 2015
CellBiosciencesBought by Bio-TechneUndisclosedJun 2014
OncoMed PharmaceuticalsListed$82MJul 2013
Pathway Medical TechnologiesBought by MEDRADUndisclosedSept 2011
Calistoga PharmaceuticalsBought by Gilead Sciences$375MFeb 2011
An exit counts when it came after the firm's first round in the company. From historical deal records.